Investigational drug · Phase 3
YJ001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Peripheral Neuropathic Pain (DPNP).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "YJ001"
First trial start
2024
Jan 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YJ001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Peripheral Neuropathic Pain (DPNP)
Approved drugs for the same conditions: Neuropathic pain · Cardiovascular and metabolic · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "YJ001" as an intervention, largest first.
- YJ001 Spray for Diabetic Peripheral Neuropathic PainPivotal-lookingRecruiting
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Industry
NCT07859111 · 400 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 30, 2028
Drug: YJ001 spray simulant; YJ001 spray and 2 more · For: Diabetic Peripheral Neuropathic Pain (DPNP)
Sites: Beijing, China
Peking University Third HospitalAcademic, hospital or other
NCT04953221 · 225 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 1, 2022
Drug: YJ001 · For: Diabetic Peripheral Neuropathic Pain
Sites: Beijing, China
- Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic PainPivotal-lookingCompleted
Zhejiang Yuejia Pharmaceuticals Co., Ltd.Industry
NCT07858344 · 196 participants · Start Jan 18, 2024 · Primary completion Dec 27, 2024
Drug: YJ001 spray simulator; YJ001 Spray 240 mg/day and 2 more · For: Diabetic Peripheral Neuropathic Pain (DPNP)
Sites: Beijing, China
Yuejia Pharmaceuticals (USA), Inc.Industry
NCT05451667 · 32 participants · Start Aug 15, 2022 · Primary completion Dec 20, 2022
Drug: YJ001 for Spray Use; Placebo of YJ001 for Spray Use · For: Safety and Tolerability
Sites: Baltimore, Maryland
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Industry
NCT06361108 · 24 participants (planned) · Start May 16, 2024 · Primary completion Dec 20, 2025
Drug: YJ001 for Spray Use; Placebo of YJ001 for Spray Use · For: Diabetic Peripheral Neuropathic Pain
Sites: Fredericksburg, Texas
Newest research
PubMed records naming it or its code names, newest first.
- First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain.
Yang X, Zhu R, Zhang J, et al. · Expert Opin Investig Drugs 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.